New Article Collection on Antipsychotic Discontinuation!
This new series of papers explores whether dose reduction or withdrawal is advisable and the risks associated with such a procedure. @sirsofficial.bsky.social Collection: go.nature.com/4pS4EA2
🏛 SIRS 2026 Elections – Nominations Open!
We’re accepting nominations for:
✨ President-Elect
✨ Board Members (6 positions)
✨ Junior Board Members (3 positions)
Help shape the Society’s future.
🗓 Deadline: 28 November 2025
🔗: sirs.societyconference.com?conf_id=1002...
#SIRS2026
👉New Article Collection!
We are proud to highlight our new article collection, Pathways to prevention: background and methodology for the Accelerating Medicines Partnership® Schizophrenia Program
@sirsofficial.bsky.social go.nature.com/495Z3Av
Schizophrenia isn’t just in the brain. 🧠💔🦴
New study (Xie et al., 2025, Schizophrenia) maps shared genetic links between SCZ and heart, bone & abdominal organ imaging traits—revealing its truly systemic nature and new therapeutic targets.
🔗 www.nature.com/articles/s41...
New research explores how childhood trauma and violence intersect in schizophrenia. Reduced connectivity between the orbitofrontal & temporal brain regions mediates this link—potential neural targets for trauma-related interventions.
🔗 www.nature.com/articles/s41...
In Clinical High Risk research, how participants are recruited matters. Recruitment sources influence sex, age, and clinical profiles, shaping the heterogeneity seen across CHR studies. Accounting for these differences is crucial when interpreting findings.
🔗 Article: www.nature.com/articles/s41...
New review addressing the knowledge gap between voice hearing in psychosis and perceptual experiences in other sensory modalities with overview of voices and altered perceptual experiences across psychotic, mood and anxiety disorders @sirsofficial.bsky.social bit.ly/3J5ibDW
A New Chapter for Schizophrenia Journal... 📖
New investigation of what lies behind the 17-year reduction in life expectancy gap between #schizophrenia patients and the general population. 2nd-gen antipsychotics and low frequency hospitalization were associated with reduced mortality @sirsofficial.bsky.social bit.ly/4gdulqF
💡 New Findings in Clozapine Pharmacokinetics
🔗 Read the study here: doi.org/10.1038/s415...
#Clozapine #Pharmacokinetics #Inflammation #Schizophrenia
📆 September is here! Your SIRS Submission Deadlines are Approaching FAST!
Be Part of the Conversation in Florence, Italy
Submit Your Symposia Proposal Today!
#SIRS2026
LINK: sirs.societyconference.com/v2/#card/sub...
This is one of the circuits which has been previously related to symptom improvements in patients with firstepisode of psychosis.
The authors found that treatment-responsive and treatment-resistant psychosis groups differed in longitudinal changes in connectivity between ventral striatal and temporal cortical regions.
New study found longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance. @sirsofficial.bsky.social bit.ly/3JHvj26
How can smartphone and wearable digital biomarkers inform about risk of developing schizophrenia? Learn more about the use of digital phenotyping in the #AMP_SZ study in this new paper #biomarkers @SIRSGlobal bit.ly/4kxW1qH
Watch Dr. Perkins discuss their work and this article: vimeo.com/1062879582?s...
Advances in proteomics & genomics are shedding light on biomarkers linked to schizophrenia risk. The AMP® Schizophrenia study is tracking 2,000+ participants to uncover blood & saliva markers that predict outcomes & reveal underlying biology. #Psychiatry #Biomarkers #AMP_SCZ bit.ly/3IB5Dn6
Watch Dr Daniel H. Mathalon discuss their work and this article: vimeo.com/1066564687
🚨 AMP SCZ EEG Study! 🧠⚡ CHR patients need better treatments. EEG biomarkers show strong reliability & potential for predicting outcomes, tracking illness, & guiding interventions #EEG bit.ly/46ungiw
Curious about predicting clinical outcomes? New paper in @schizjournal.bsky.social special issue shows how multidisciplinary experts shaped the AMP #Schizophrenia analysis strategy. Explore key decisions & data-driven insights! @sirsofficial.bsky.social @NoraPenzel @poloscience go.nature.com/4lYwQzv
Watch the interview with Dr. Kapur @tkapur.bsky.social, Dr. Lewandowski, and Carlos Larrauri vimeo.com/1050068801
Getting lived experience to guide psychosis research: The AMP® SCZ program integrates voices of those with lived experience into every stage to foster trust, enhance research outcomes, and inform future strategies for treatment and prevention @sirsofficial.bsky.social go.nature.com/4lIGYfu
Dr Jean Addington discusses the challenges and highlights the most important aspects of the selection and application of clinical assessment and outcome measures in the large multisite AMP®SCZ study investigating CHR go.nature.com/4cHoQ1r @sirsofficial.bsky.social vimeo.com/1040425281
Watch Dr. Martha E. Shenton discuss her work vimeo.com/1065077556?share=copy#t=0
Watch Drs. Barnaby Nelson and Scott W. Woods discuss their work vimeo.com/1065077703?share=copy#t=0
New pathways for preventing schizophrenia: public and private partners collaborate in the international Accelerating Medicines Partnership® Schizophrenia consortium @sirsofficial.bsky.social go.nature.com/3Y89zks
Our new paper titled "The MR #neuroimaging protocol for the Accelerating Medicines Partnership® #Schizophrenia Program" is now published in @schizjournal.bsky.social
www.nature.com/articles/s41...
Late highlight at #SIRS2025 @sirsofficial.bsky.social well worth staying for: symposium on cognitive impairments in psychosis, with chairs @rob-mccutcheon.bsky.social & Ingrid Melle (pic), and Sherry KW Chan, David Lewis, Richard Keefe - highlighting course, contributors, and ways forward.
